Calliditas Therapeutics AB (publ) reaffirmed earnings guidance for the year ending December 31, 2024. For the year, the company expects continued revenue growth: total net sales are estimated to be USD 150-180 million for the year ending December 31, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
205.4 SEK | +0.29% |
|
-1.34% | +61.61% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.61% | 1.05B | |
+15.02% | 9.25B | |
+42.06% | 4.45B | |
-22.01% | 4.43B | |
+8.28% | 4.03B | |
+11.22% | 2.24B | |
-26.61% | 2.18B | |
+11.64% | 2.02B | |
-42.69% | 1.79B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- CALTX Stock
- News Calliditas Therapeutics AB
- Calliditas Therapeutics AB Reaffirms Earnings Guidance for the Year Ending December 31, 2024